Huntsville, ALNCT07340320Now EnrollingIRB Ready

Type II Diabetes Mellitus Clinical Trial in Huntsville, AL

Access cutting-edge type ii diabetes mellitus treatment through this clinical trial at a research site in Huntsville. Study-provided care at no cost to qualified participants.

Sponsored by Corxel Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Huntsville location

Preparing your pre-screening questions…

Expert Care in Huntsville

Access type ii diabetes mellitus specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related type ii diabetes mellitus treatment provided free

Apply for This Huntsville Location

Check if you qualify for this type ii diabetes mellitus clinical trial in Huntsville, AL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Huntsville

    Convenient for AL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Huntsville site if eligible
  4. 4Begin participation

About This Type II Diabetes Mellitus Study in Huntsville

This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days. The study is being done at multiple medical centers. Participants are assigned by chance (randomized) to different groups, and neither the participants nor the study staff know which group they're in (double-blind). The groups are compared side by side (parallel), and some participants will receive inactive pills (placebo) to help measure the true effect of the study drug. After screening, participants will be randomly placed into one of six groups, with equal chances of being in any group. Each group will receive a different dose of CX11 or a placebo. Treatment will last 24 weeks. After that, all participants will have a 2-week follow-up period to check on safety.

Sponsor: Corxel Pharmaceuticals

Who Can Participate

Inclusion Criteria

Participants who meet all of the following criteria will be eligible to participate in this study:
Adults aged 18 to 75.
Diagnosis of type 2 diabetes for at least 6 months.
HbA1c between 7.0% and 10.5%.
Body mass index (BMI) between 23 and 50 kg/m².
Body weight stable for the past 3 months before joining.
Stable dose of metformin (≥1000 mg/day), with or without SGLT2i, for ≥3 months.
Women of childbearing potential (WOCBP): highly effective contraception ≥6 months prior to screening, throughout study, and 90 days post-last dose; negative pregnancy test within 24 hrs of first dose; no intent to donate sperm/ova
Agrees to avoid grapefruit/grapefruit products

Exclusion Criteria

Participants who meet any of the following criteria will be excluded from this study:
Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or systemic corticosteroids).
Type 1 diabetes or a history of diabetic ketoacidosis.
Use of any GLP-1 receptor agonist within the past 6 months, or any prior exposure to CX11.
Use of insulin to control blood sugar within the past 12 months.
More than one episode of severe low blood sugar, with awareness of hypoglycemia symptoms.
Cardiovascular or cerebrovascular conditions within the past 6 months:
Heart attack, coronary angioplasty, or bypass surgery (diagnostic angiography allowed).
Valvular heart disease or prior heart valve repair surgery.
Unstable angina.
Transient ischemic attack (TIA) or stroke.
Decompensated heart failure (NYHA Class III or IV).
ECG abnormalities indicating significant safety risk, such as supraventricular tachycardia, torsades de pointes, second- or third-degree AV block, myocardial infarction, QTcF \> 450 ms in males or \> 470 ms in females, PR interval \> 220 ms.
Poorly controlled hypertension at screening: systolic ≥ 180 mmHg or diastolic ≥ 100 mmHg.
Pancreatic or gallbladder conditions:
Acute or chronic pancreatitis.
Symptomatic gallbladder disease (previous cholecystectomy is allowed).
Pancreatic injury or risk factors that increase pancreatitis risk.
Thyroid conditions:
Poorly controlled abnormal thyroid function on a stable dose before screening.
Clinically significant abnormal thyroid test results at screening.
Personal or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) type 2A or 2B.
Cancer history:
Malignancy within the past 5 years, regardless of recurrence or metastasis. Exceptions: localized basal cell skin cancer, low-risk prostate cancer, cervical carcinoma in situ, or high-grade prostatic intraepithelial neoplasia.
Gastrointestinal conditions or treatments that may affect drug absorption:
Abnormal gastric emptying (e.g., gastric outlet obstruction).
Severe chronic gastrointestinal disease, including active ulcer within 6 months.
Crohn's disease, ulcerative colitis, or other inflammatory bowel diseases.
Prior gastrointestinal surgery (except polypectomy and appendectomy).
Long-term use of drugs that directly affect gastrointestinal motility (e.g., mosapride, cisapride).
Liver disease:
Active liver disease other than nonalcoholic fatty liver.
Chronic active hepatitis B or C.
Primary biliary cirrhosis.
Eye disease:
Uncontrolled or potentially unstable diabetic retinopathy or maculopathy.
Abnormal lab results at screening:
eGFR \< 60 mL/min/1.73 m² (CKD-EPI).
ALT or AST \> 2.5 × upper limit of normal (ULN).
Total bilirubin \> 1.5 × ULN (except known Gilbert's syndrome).
Serum amylase or lipase \> 1.5 × ULN.
Fasting triglycerides \> 5.7 mmol/L.
TSH \> 1.5 × ULN or \< 1.0 × LLN.
Calcitonin ≥ 20 ng/L.
Hemoglobin \< 110 g/L (male) or \< 100 g/L (female).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Huntsville?

Yes, this clinical trial (NCT07340320) has an active research site in Huntsville, AL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Type II Diabetes Mellitus Treatment Options in Huntsville, AL

If you're searching for type ii diabetes mellitus treatment options in Huntsville, AL, this clinical trial (NCT07340320) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Huntsville research site is actively enrolling participants for this clinical trial. You'll receive care from experienced type ii diabetes mellitus specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all type ii diabetes mellitus clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Huntsville, AL

See all pulmonary embolism clinical trials recruiting in Huntsville — not just this study.

Browse Pulmonary Embolism Trials in Huntsville →

Browse More Trials by Condition

Pulmonary Embolism TrialsEssential Tremor TrialsType 2 Diabetes TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Huntsville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Huntsville, AL